Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Patient Groups Push Back against Delisting OTC-Like Drugs; Panel Leans Toward Higher Copays
November 21, 2025
- Japan Approves Label Expansions for Braftovi, Augtyro, Uplizna, and More
November 21, 2025
- Japan Panel OKs NIP Use of Maternal RSV Vaccine from FY2026
November 21, 2025
- Japan to Add High-Dose Flu Vaccine to NIP for Adults Aged 75 and Over
November 21, 2025
- MHLW Panel to Review Kissei’s Uterine Fibroid Drug, 3 More NMEs on December 3
November 21, 2025
- Ueno Signals Openness to Multiple Approaches on OTC-Like Drug Copays
November 21, 2025
- LDP Outlines Key Issues for FY2026 Budget, Copay Review for OTC-Like Drugs Included
November 21, 2025
- Japan to Tap National Anti-Flu Drug Stockpile during Severe Shortages: MHLW
November 21, 2025
- Ensure Sustainable Drug Pricing for National Security: LDP Health Division Chief
November 21, 2025
- Chuikyo Discusses Lower Prices for Low-Novelty Drugs, PMP Criteria, Re-Pricing
November 20, 2025
- Chuikyo Split over How to Ease Negative Margins
November 20, 2025
- Providers Urging Possible Price Measures over Packaging Misalignment
November 20, 2025
- Providers Push to Expand 2% Buffer Zone in Drug Price Revisions as Costs Rise
November 20, 2025
- Japan Moves to Advance “G1” Price Cuts by 5 Years under Proposed LLP Overhaul
November 20, 2025
- MHLW to Scrutinize Outcomes for 12 Firms Yet to Strike MFN Deals
November 20, 2025
- Govt Weighs Additional Copays for OTC-Like Drugs in Economic Package
November 19, 2025
- LDP Study Group Submits Emergency Proposal to Health Minister, Seeks 5% Drug Price Hike
November 19, 2025
- Japan Launches Pilot Expert Committee System for Patent Linkage Reviews, Aims to Reduce IP Feuds
November 17, 2025
- Chuikyo Split over Higher Copays under LLP Scheme; Payer Push Meets Provider Caution
November 17, 2025
- Elrexfio to Escape CEA-Based Price Tweak, Analysis to Resume for Paxlovid
November 17, 2025
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…